Dr. Reddy's Laboratories (RDY) total debt
Dr. Reddy's Laboratories (RDY) carried total debt of ₹77.34B at the end of fiscal 2026 (March 31, 2026). That is 65.4% higher than the ₹46.77B of fiscal 2025. Figures as of 18 Nov 2026, 09:50 UTC, from Yahoo Finance.
Key facts
- Total debt, fiscal 2026
- ₹77.34B
- Change on fiscal 2025
- +65.4%
- Highest on record
- ₹77.34Bfiscal 2026
- Lowest on record
- ₹13.47Bfiscal 2023
- Fiscal years on record
- 42023–2026
Figures as of . Statements from Yahoo Finance. Amounts are in INR. Figures, not advice.
Dr. Reddy's Laboratories total debt, in more detail
Across the 4 fiscal years on record (2023–2026), the highest was ₹77.34B in fiscal 2026 and the lowest ₹13.47B in fiscal 2023.
Total debt was 0.2× shareholders' equity at the end of fiscal 2026.
Total debt by fiscal year
Dr. Reddy's Laboratories total debt, year by year
| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
|---|---|---|---|---|
| 2026 | ₹77.34B | 65.4% up | 0.2× | |
| 2025 | ₹46.77B | 133.6% up | 0.1× | |
| 2024 | ₹20.02B | 48.6% up | 0.1× | |
| 2023 | ₹13.47B | — | 0.1× |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
How to read it
Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.
Total debt at health care companies of similar size
| Company | Total debt | Fiscal year |
|---|---|---|
| Smith & Nephew SNN | $3.33B | 2025 |
| Penumbra PEN | $219.70M | 2025 |
| Dr. Reddy's Laboratories RDY | ₹77.34B | 2026 |
| Align Technology ALGN | $114.45M | 2025 |
| Cooper Companies COO | $2.51B | 2025 |
| Fresenius Medical Care FMS | €10.80B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Dr. Reddy's Laboratories, figure by figure
- Dr. Reddy's Laboratories market cap
- Dr. Reddy's Laboratories revenue
- Dr. Reddy's Laboratories earnings
- Dr. Reddy's Laboratories earnings per share (EPS)
- Dr. Reddy's Laboratories P/E ratio
- Dr. Reddy's Laboratories P/S ratio
- Dr. Reddy's Laboratories P/B ratio
- Dr. Reddy's Laboratories free cash flow
- Dr. Reddy's Laboratories operating margin
- Dr. Reddy's Laboratories dividend
- Dr. Reddy's Laboratories shares outstanding
- Dr. Reddy's Laboratories cash on hand
- Dr. Reddy's Laboratories total assets
- Dr. Reddy's Laboratories return on equity (ROE)
- Dr. Reddy's Laboratories return on invested capital (ROIC)
Dr. Reddy's Laboratories (RDY) overview: price, valuation and scorecardAll health care companies by market value
Dr. Reddy's Laboratories total debt: questions and answers
How much debt does Dr. Reddy's Laboratories have?
Dr. Reddy's Laboratories (RDY) carried total debt of ₹77.34B at the end of fiscal 2026 (March 31, 2026). That is 65.4% higher than the ₹46.77B of fiscal 2025.
What are the highest and lowest total debt figures on record for Dr. Reddy's Laboratories?
Across the 4 fiscal years on record (2023–2026), the highest was ₹77.34B in fiscal 2026 and the lowest ₹13.47B in fiscal 2023.
How does Dr. Reddy's Laboratories's debt compare with its equity?
Total debt was 0.2× shareholders' equity at the end of fiscal 2026.
How is Dr. Reddy's Laboratories's total debt calculated?
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative. For Dr. Reddy's Laboratories it is on record here for 4 fiscal years, 2023 to 2026.
Fiscal years are named for the calendar year they end in.
Learn: total debt
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Dr. Reddy's Laboratories (RDY) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/RDY/total-debt
Underlying data: Yahoo Finance.